Literature DB >> 11274422

The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein.

T Matsutake1, P K Srivastava.   

Abstract

CD4(+) T lymphocyte clones, generated from mice immunized with the methylcholanthrene-induced fibrosarcoma Meth A (H-2(d)), are restricted by I-E(d) and recognize a unique antigen on Meth A. The antigen has been purified and characterized as the ribosomal protein L11. The antigenic epitope is contained within the sequence EYELRKHNFSDTG and is generated by substitution of Asn by His (italic) caused by a single point mutation. The tumor contains the wild-type and the mutated alleles. Immunization of BALB/cJ mice with the mutated epitope but not with the wild-type epitope protects mice against a subsequent challenge with the Meth A sarcoma. Adoptive transfer of CD4(+) clones into BALB/c mice renders the mice specifically resistant to Meth A sarcoma. The mutated L11 epitope is thus shown to be an immunoprotective epitope in vivo by several criteria.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11274422      PMCID: PMC31167          DOI: 10.1073/pnas.071523398

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Isolation of Chinese hamster ovary ribosomal mutants differentially resistant to ricin, abrin, and modeccin.

Authors:  S Sallustio; P Stanley
Journal:  J Biol Chem       Date:  1990-01-05       Impact factor: 5.157

2.  The primary structure of rat ribosomal protein L11.

Authors:  Y L Chan; J Olvera; V Paz; I G Wool
Journal:  Biochem Biophys Res Commun       Date:  1992-05-29       Impact factor: 3.575

Review 3.  Individually distinct transplantation antigens of chemically induced mouse tumors.

Authors:  P K Srivastava; L J Old
Journal:  Immunol Today       Date:  1988-03

Review 4.  Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells.

Authors:  P D Greenberg
Journal:  Adv Immunol       Date:  1991       Impact factor: 3.543

5.  Expression of a shared tumor-specific antigen by two chemically induced BALB/c sarcomas.

Authors:  M A Palladino; P K Srivastava; H F Oettgen; A B DeLeo
Journal:  Cancer Res       Date:  1987-10-01       Impact factor: 12.701

6.  Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo.

Authors:  H Udono; D L Levey; P K Srivastava
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

7.  A mouse mutant p53 product recognized by CD4+ and CD8+ T cells.

Authors:  Y Noguchi; Y T Chen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

8.  Structure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptide.

Authors:  C Sibille; P Chomez; C Wildmann; A Van Pel; E De Plaen; J L Maryanski; V de Bergeyck; T Boon
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

9.  Effect of in vivo administration of Lyt antibodies. Lyt phenotype of T cells in lymphoid tissues and blocking of tumor rejection.

Authors:  E Nakayama; A Uenaka
Journal:  J Exp Med       Date:  1985-02-01       Impact factor: 14.307

10.  The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice.

Authors:  B Van den Eynde; B Lethé; A Van Pel; E De Plaen; T Boon
Journal:  J Exp Med       Date:  1991-06-01       Impact factor: 14.307

View more
  17 in total

1.  Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function.

Authors:  Amy D H Doody; Joseph T Kovalchin; Marianne A Mihalyo; Adam T Hagymasi; Charles G Drake; Adam J Adler
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

2.  High efficiency CD91- and LOX-1-mediated re-presentation of gp96-chaperoned peptides by MHC II molecules.

Authors:  Toyoshi Matsutake; Tatsuya Sawamura; Pramod K Srivastava
Journal:  Cancer Immun       Date:  2010-08-02

3.  Ribosomal versus non-ribosomal cellular antigens: factors determining efficiency of indirect presentation to CD4+ T cells.

Authors:  Mary Philip; Andrea Schietinger; Hans Schreiber
Journal:  Immunology       Date:  2010-03-16       Impact factor: 7.397

Review 4.  Targeting cancer-specific mutations by T cell receptor gene therapy.

Authors:  Thomas Blankenstein; Matthias Leisegang; Wolfgang Uckert; Hans Schreiber
Journal:  Curr Opin Immunol       Date:  2015-02-27       Impact factor: 7.486

Review 5.  "It is the antigen(s), stupid" and other lessons from over a decade of vaccitherapy of human cancer.

Authors:  Matthew R Buckwalter; Pramod K Srivastava
Journal:  Semin Immunol       Date:  2008-08-20       Impact factor: 11.130

6.  Identification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide.

Authors:  Ronald C Hendrickson; Vito R Cicinnati; Andreas Albers; Grzegorz Dworacki; Andrea Gambotto; Ornella Pagliano; Thomas Tüting; Jose I Mayordomo; Carmen Visus; Ettore Appella; Jeffrey Shabanowitz; Donald F Hunt; Albert B DeLeo
Journal:  Cancer Immunol Immunother       Date:  2009-06-27       Impact factor: 6.968

7.  Covalent crosslinking of tumor antigens stimulates an antitumor immune response.

Authors:  Yanping Wang; Xiang-Yang Wang; John R Subjeck; Hyung L Kim
Journal:  Vaccine       Date:  2010-08-02       Impact factor: 3.641

8.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

9.  Modeling the repertoire of true tumor-specific MHC I epitopes in a human tumor.

Authors:  Nisheeth Srivastava; Pramod K Srivastava
Journal:  PLoS One       Date:  2009-07-10       Impact factor: 3.240

10.  Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition.

Authors:  Mu-Shui Dai; Shelya X Zeng; Yetao Jin; Xiao-Xin Sun; Larry David; Hua Lu
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.